This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kashani-Sabet, M. Articles by Sagebiel, R. W. Search for Related Content PubMed PubMed Citation Articles by Kashani-Sabet, M. Articles by Sagebiel, R. W. Social Bookmarking                            What's this?

NF-B in the Vascular Progression of Melanoma

From the Auerback Melanoma Research Laboratory and Melanoma Center, Cutaneous Oncology Program, Cancer Center, University of California San Francisco; and California Pacific Medical Research Institute, San Francisco, San Francisco, CA

Address reprint requests to Mohammed Kashani-Sabet, MD, University of California San Francisco Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA 94115; e-mail: kashanim{at}derm.ucsf.edu

PURPOSE: To examine a model of melanoma progression based on vascular factors and the role of NF-B in the vascular progression of melanoma.

PATIENTS AND METHODS: A data set of 526 patients from the University of California San Francisco Melanoma Center with 2 years of follow-up or first relapse was studied. The impact of the presence or absence of various prognostic factors on overall survival of melanoma patients was assessed using Cox regression and Kaplan-Meier analysis. A matched-pair analysis of NF-B expression was performed in cases with vascular involvement and increased tumor vascularity versus matched controls lacking these factors.

RESULTS: Cox regression analysis of factors evaluated by the American Joint Committee on Cancer Melanoma Staging Committee reproduced the powerful impact of tumor thickness and ulceration in this data set. With the inclusion of vascular factors such as tumor vascularity and vascular involvement, ulceration was no longer significant in predicting overall survival. By multivariate analysis, vascular involvement and tumor vascularity were the strongest predictors of melanoma outcome. Tumor vascularity seems to be a precursor of both vascular involvement and ulceration. A matched-pair tissue array analysis demonstrated the significant correlation between overexpression of NF-B–p65 and the development of vascular factors.

CONCLUSION: Vascular factors play an important role in the progression of malignant melanoma. Ulceration may be a surrogate marker for the interactions between melanoma and the tumor vasculature. NF-B seems to play an important role in the development of these factors.

Supported by an educational grant from the Skin Disease Research Foundation (San Francisco, CA) and the Mark Shafir Fund.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Kashani-Sabet, S. Venna, M. Nosrati, J. Rangel, A. Sucker, F. Egberts, F. L. Baehner, J. Simko, S. P.L. Leong, C. Haqq, et al. A Multimarker Prognostic Assay for Primary Cutaneous Melanoma Clin. Cancer Res., November 15, 2009; 15(22): 6987 - 6992. [Abstract] [Full Text] [PDF]

				M. Kashani-Sabet, J. Rangel, S. Torabian, M. Nosrati, J. Simko, D. M. Jablons, D. H. Moore, C. Haqq, J. R. Miller III, and R. W. Sagebiel A multi-marker assay to distinguish malignant melanomas from benign nevi PNAS, April 14, 2009; 106(15): 6268 - 6272. [Abstract] [Full Text] [PDF]

				I. Roodink, G. Kats, L. van Kempen, M. Grunberg, C. Maass, K. Verrijp, J. Raats, and W. Leenders Semaphorin 3E Expression Correlates Inversely with Plexin D1 During Tumor Progression Am. J. Pathol., December 1, 2008; 173(6): 1873 - 1881. [Abstract] [Full Text] [PDF]

				P Ceppi, M Volante, S Novello, I Rapa, K. Danenberg, P. Danenberg, A Cambieri, G Selvaggi, S Saviozzi, R Calogero, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann. Onc., December 1, 2006; 17(12): 1818 - 1825. [Abstract] [Full Text] [PDF]

				J. Rangel, S. Torabian, L. Shaikh, M. Nosrati, F. L. Baehner, C. Haqq, S. P.L. Leong, J. R. Miller III, R. W. Sagebiel, and M. Kashani-Sabet Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma J. Clin. Oncol., October 1, 2006; 24(28): 4565 - 4569. [Abstract] [Full Text] [PDF]

				D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]

				G.-S. Liu, L.-F. Liu, C.-J. Lin, J.-C. Tseng, M.-J. Chuang, H.-C. Lam, J.-K. Lee, L.-C. Yang, J. H. Y. Chan, S.-L. Howng, et al. Gene Transfer of Pro-opiomelanocortin Prohormone Suppressed the Growth and Metastasis of Melanoma: Involvement of {alpha}-Melanocyte-Stimulating Hormone-Mediated Inhibition of the Nuclear Factor {kappa}B/Cyclooxygenase-2 Pathway Mol. Pharmacol., February 1, 2006; 69(2): 440 - 451. [Abstract] [Full Text] [PDF]

				S. Yang, K. Irani, S. E. Heffron, F. Jurnak, and F. L. Meyskens Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor Mol. Cancer Ther., December 1, 2005; 4(12): 1923 - 1935. [Abstract] [Full Text] [PDF]

				F. R. Hirsch, M. Varella-Garcia, J. McCoy, H. West, A. C. Xavier, P. Gumerlock, P. A. Bunn Jr, W. A. Franklin, J. Crowley, and D. R. Gandara Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study J. Clin. Oncol., October 1, 2005; 23(28): 6838 - 6845. [Abstract] [Full Text] [PDF]

				D. R. Gandara and P. H. Gumerlock Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Chemotherapy: Case Closed or Is the Jury Still Out? J. Clin. Oncol., September 1, 2005; 23(25): 5856 - 5858. [Full Text] [PDF]

				R. Perez-Soler and L. Saltz Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining? J. Clin. Oncol., August 1, 2005; 23(22): 5235 - 5246. [Abstract] [Full Text] [PDF]

				L. Shaikh, R. W. Sagebiel, C. M. M. Ferreira, M. Nosrati, J. R. Miller III, and M. Kashani-Sabet The Role of Microsatellites as a Prognostic Factor in Primary Malignant Melanoma Arch Dermatol, June 1, 2005; 141(6): 739 - 742. [Abstract] [Full Text] [PDF]

				C. M. Balch, S.-J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr., J. M. Kirkwood, et al. An Evidence-based Staging System for Cutaneous Melanoma CA Cancer J Clin, May 1, 2004; 54(3): 131 - 149. [Abstract] [Full Text] [PDF]